Devic's neuromyelitis optica is an inflammatory demyelinating disorder normally restricted to the optic nerves and spinal cord. Since the identification of a specific autoantibody directed against aquaporin 4, neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody, neuromyelitis optica has been considered an entity distinct from multiple sclerosis. Recent findings indicate that the neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody has a pathogenic role through complementdependent astrocyte toxicity. However, the link with demyelination remains elusive. Autoantibodies can act as receptor agonists/antagonists or alter antigen density in their target cells. We hypothesized that the neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody impairs astrocytic function and secondarily leads to demyelination. Rat astrocytes and oligodendrocytes from primary cultures and rat optic nerves were exposed long-term (24 h) to immunoglobulin G in the absence of complement. Immunoglobulin G was purified from the serum of patients with neuromyelitis optica who were either neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody positive or negative, as well as from healthy controls. Flow cytometry analysis showed a reduction of membrane aquaporin 4 and glutamate transporter type 1 on astrocytes following contact with immunoglobulin G purified from neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody positive serum only. The activity of glutamine synthetase, an astrocyte enzyme converting glutamate into glutamine, decreased in parallel, indicating astrocyte dysfunction. Treatment also reduced oligodendrocytic cell processes and approximately 30% oligodendrocytes died. This deleterious effect was confirmed ex vivo; exposed optic nerves showed reduction of myelin basic protein. Immunoglobulin G from neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody seronegative patients and from healthy controls had no similar effect. Neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody did not directly injure oligodendrocytes cultured without astrocytes. A toxic bystander effect of astrocytes damaged by neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody on oligodendrocytes was identified. Progressive accumulation of glutamate in the culture medium of neuromyelitis opticaimmunoglobulin G/aquaporin 4-antibody-treated glial cells supported the hypothesis of a glutamate-mediated excitotoxic death of oligodendrocytes in our models. Moreover, co-treatment of glial cultures with neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody and D+2-amino-5-phosphonopentanoic acid, a competitive antagonist at the N-methyl-D-aspartate/ glutamate receptor, partially protected oligodendrocytes. Co-immunolabelling of oligodendrocyte markers and neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody showed that astrocytic positive processes were in close contact with oligodendrocytes and myelin in rat optic nerves and spinal cord, but far less so in other parts of the central nervous system. This suggests a bystander effect of neuromyelitis optica-immunoglobulin G-damaged astrocytes on oligodendrocytes in the nervous tissues affected by neuromyelitis optica. In conclusion, in these cell culture models we found a direct, complement-independent effect of neuromyelitis optica-immunoglobulin G/aquaporin 4 antibody on astrocytes, with secondary damage to oligodendrocytes possibly resulting from glutamate-mediated excitotoxicity. These mechanisms could add to the complement-induced damage, particularly the demyelination, seen in vivo.
Introduction
Devic's neuromyelitis optica is an inflammatory demyelinating disorder of the central nervous system normally restricted to the optic nerves and the spinal cord (Devic, 1894; Wingerchuk et al., 2007) . It is characterized by severe attacks of optic neuritis and myelitis leading in most cases to loss of vision, motor weakness, bladder dysfunction and sensory failure. The pathology is characterized by extensive demyelination and axonal loss in both white and grey matter (Lucchinetti et al., 2002 ). Devic's neuromyelitis optica has frequently been considered a subtype of multiple sclerosis but recent clinical, epidemiological, pathological and immunological data support the view that it is a distinct entity to multiple sclerosis (O'Riordan et al., 1996; Wingerchuk et al., 1999; De Sè ze et al., 2002) . A specific autoantibody, neuromyelitis optica-immunoglobulin G (NMO-IgG), has been identified (Lennon et al., 2004) . The target antigen for NMO-IgG is a water channel protein, aquaporin 4 (AQP4) (Lennon et al., 2005) . In the central nervous system, AQP4 is organized in heterotetramers that are expressed mainly on the plasma membrane of astrocytes and concentrated in domains that face endothelial basal membranes (Amiry-Moghaddam et al., 2003) . AQP4 is not expressed in oligodendrocytes. Studies in knockout mice show that AQP4 plays a role in brain water homeostasis, astrocytic glutamate transport and neural cell excitability (Verkman et al., 2006; Ding et al., 2007; Zeng et al., 2007) .
Recent findings support a direct pathogenic role for NMO-IgG/ AQP4 antibodies in Devic's neuromyelitis optica. Depositions of immunoglobulins (Ig) and complement are preferentially located in areas of high AQP4 expression and AQP4 is selectively lost in active Devic's neuromyelitis optica lesions (Misu et al., 2007; Roemer et al., 2007) . In animal models, intraperitoneal injection of human sera containing NMO-IgG/AQP4 antibodies induces neuromyelitis optica-like lesions with T cell mediated brain inflammation (Bradl et al., 2009) . More recently, similar lesions were induced by intracerebral co-injection of human sera containing NMO-IgG/AQP4 antibodies and human complement (Saadoun et al., 2010) but not by injection of human sera containing NMO-IgG/AQP4 antibodies alone. In vitro, binding of NMOIgG/AQP4 antibodies to AQP4 initiates complement activation and complement-dependent cytotoxicity on astrocytes (Hinson et al., 2007; Kinoshita et al., 2009; Sabater et al., 2009) . All these findings highlight the important role of complement in the pathogenesis of Devic's neuromyelitis optica. However, it is now well established that, besides activating the complement cascade, antibodies may also act as specific receptor agonists or antagonists, or alter antigen density in target cells (Diamond et al., 2009) . It was recently shown that, in absence of complement, NMO-IgG/AQP4 antibody binding induced a reversible internalization of the AQP4-IgG complex and loss of the glutamate transporter 1/excitatory aminoacid transporter 2 (Hinson et al., 2008) . We hypothesized that demyelination in Devic's neuromyelitis optica lesions partly resulted from an indirect deleterious effect of NMO-IgG/AQP4 antibodies on oligodendrocytes mediated by impairment of astrocyte function. Alterations of astrocyte metabolism in various other experimental and pathological conditions result in oligodendrocyte cell death and demyelination (Matute et al., 2007) . We therefore analysed: (i) the effect of NMO-IgG/AQP4 antibodies in the absence of complement on astrocyte function in glial cell cultures and in optic nerve preparations; (ii) the effect of NMO-IgG/AQP4 antibodies on oligodendrocyte integrity and survival in these models; and (iii) the spatial association between NMO-IgG/AQP4 antibody immunoreactive astrocytes and oligodendrocytes in optic nerves and spinal cord.
Materials and methods
Human sera and IgG isolated from patient sera Sera were obtained from eight patients with a Devic's neuromyelitis optica spectrum disorder (Wingerchuk et al., 2007) ; six sera were positive for NMO-IgG and AQP4 antibody and two were negative with both techniques. Characteristics of patients with Devic's neuromyelitis optica are presented in Table 1 . We also used control sera collected from five healthy blood donors at Etablissement Franç ais du Sang. IgG from the eight Devic's neuromyelitis optica and five control sera were purified on Protein-A Sepharose 4 Fast Flow TM beads (GE Healthcare-Life Science) and eluted with glycine 0.1 M buffer pH 2.8 then neutralized in Tris 1.5 M pH 8.8. Samples were concentrated or diluted to obtain an IgG concentration of 0.2 mg/ml. All samples were heated for de-complementation (56 C, 30 min) before being used for experiments. NMO-IgG immunoreactivity was assessed using the classic formol fixation on rat brain as previously described (Marignier et al., 2008) . NMO-IgG positive sera have been validated to contain anti-AQP4 antibody using a cell based assay with AQP4-transfected cells (positive result in Supplementary Fig. 1 ) and a fluorescence-based immunoprecipitation assay routinely used in the laboratory. NMO-IgG seronegative sera from two patients with Devic's neuromyelitis optica and healthy donors were validated as negative for AQP4 antibodies detection by fluorescence based immunoprecipitation and cell-based assays. 
Tissue preparation and glial cell cultures
Rats (OFA, Elevage Janvier, France) received intracardiac infusion with 15 ml phosphate buffered saline (PBS; 0.1 M pH 7.4) (solution at room temperature) to eliminate red blood cells, then with 15 ml 4% paraformaldehyde (solution on ice). We previously compared two tissue fixation methods (10% formol and 4% paraformaldehyde) and showed that in the formol fixed tissues, NMO-IgG immunoreactivity concentrated in astrocytic foot processes around blood vessels, as expected. By contrast, with 4% paraformaldehyde fixation, NMO-IgG immunoreactivity was predominantly present in the processes and soma of astrocytes ( Supplementary Fig. 3 ). Following removal from the skull and spinal column, post-fixation of brain, optic nerve and spinal cord was performed in 4% paraformaldehyde for 2 h at 4 C (2 h minimum, 18 h maximum) then stored in 15% sucrose (diluted in PBS) at 4 C. Just before immunocytochemistry, brain was placed in 30% sucrose overnight, then embedded in Titerteck Õ preparation, frozen in isopentane at À50 C and prepared as 8-10 micron sections on a cryomicrotome. These slices were used for NMO-IgG immunostaining. Primary glial cultures were obtained by mechanical disruption of microdissected cortices from 1-day-old rat pups. For mixed glial culture (astrocytes-oligodendrocytes), dissociated cells were diluted to a density of 2 Â 10 5 cells/ml in Dulbecco's modified Eagle medium (DMEM) minimal essential Glutamax medium (Gibco, Life technologies France) containing 4.5 g/l glucose, supplemented with 20% heat-inactivated foetal calf serum and gentamycin (1 mg/ml). Cells were seeded in 6-well plate pre-coated with poly-L-lysine (3 mg/ml in 0.1 M borate buffer, pH 8.4). Cultures were incubated at 37 C in a moist 5% CO 2 , 95% air atmosphere. The medium was changed every 3 days after plating (10% foetal calf serum). Using this procedure we typically obtained a culture composed of $50% astrocytes and 50% oligodendrocytes [as systematically determined by glial fibrillary acidic protein (GFAP) and 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase (CNPase)
immunostaining, respectively; Supplementary Fig. 2A ]. For primary 
, platelet-derived growth factor and basic fibroblast growth factor (Sigma-Aldrich), to promote oligodendrocyte progenitors in gliosphere. The culture was then differentiated in CNPase positive oligodendrocytes for 2-3 days in DMEM containing 20% foetal calf serum ( Supplementary Fig. 2B ). Mixed glial, astrocyte and oligodendrocyte cultures were used for antibody treatment.
Isolated optic nerves were dissected from adult rats and put immediately on 30 mm semi-permeable membrane inserts (Millicell-CM, Millipore) in a 6-well plate containing 1 ml of culture medium (50% minimum essential medium Gibco, 25% Hank's balanced salt solution, 25% heat-inactivated horse serum, 1% L-glutamine 200 mM and 6.6 mg/ml glucose) in each well. One day later they were used for antibody treatment.
Glial culture and optic nerves were treated, when appropriate, 
Immunodetection NMO-IgG immunostaining
NMO-IgG immunostaining was performed on fixed slices of neural tissue. To avoid staining of non-organ specific autoantibody, neural slices were pre-incubated for 1.5 h in normal goat serum (10%).
Patient sera were diluted (1/50) in phosphate buffer 0.1 M pH 7.4 and incubated with slices overnight (room temperature or 4 C).
Three washes with PBS eliminated non-bound material. Bound human IgG was detected using Alexa-488 labelled anti-human IgG antibody directed against all human IgG subclasses (1/500 in PBS, 1.5 h at room temperature) (Molecular Probes A11013, USA). Following three washes in PBS, slides were prepared with Fluoroprepß solution and coverslides for fluorescence microscopy.
Specific immunodetection
Specific immunodetection of astrocyte, oligodendrocyte and endothelial cell markers was similarly performed on glial cell culture and slices of neural tissue. Astrocyte was visualized using GFAP immunolabelling, oligodendrocytes using CNPase and CRMP5 immunolabelling (cell culture and optic nerve, respectively). Polyclonal or monoclonal sera were directed to CNPase (C5922, Sigma, USA), CRMP5 (Ricard et al., 2000) , myelin basic protein (MBP, MCA70, antibody-D, Serotec), H200 neurofilament (AHP245, antibody-D, Serotec), GFAP (Z0334, Dako), Factor VIII (A0082, Dako), NMDA receptor-2B (AB1557P Chemicon International) or NMDA receptor-1 (AB9864, Millipore TM ) followed by fluorescein-conjugated anti-rabbit or anti-mouse IgG (Alexa 488-GAR and 488-GAM, Molecular Probes). Water channel and glutamate transporter were immunodetected using rabbit anti-AQP4 (AB2218, Millipore TM ) and anti-GLT1 polyclonal antibodies. Detection of active caspase-3 by anti-cleaved caspase-3/Asp175 antibody (#9661, Cell Signalling Technology Inc.) evidenced apoptotic cell death. Glial cells were fixed for 10 min in 4% paraformaldehyde for NMDA receptor subunit detection. MBP immunostaining intensity was evaluated using Analysis Õ software (10 different microscopic fields per condition, three treated and three untreated optic nerves).
Flow cytometry
Flow cytometry was performed on untreated glial cell cultures and following 24 h IgG treatment. Cells were detached from culture dishes using enzyme solution RDB (1/100, 10 min, 37 C), then washed in DMEM, incubated for 1 h at 37 C in DMEM supplemented with 20% foetal calf serum to restore surface proteins, then blocked by pre-incubation (20 min, 4 C) with anti-CD32 antibody to avoid non-specific staining. Following cell wash in 1 ml cold PBS, cells were incubated with antibody directed against surface proteins GLT1, AQP4 (AB2218, Millipore ) and CNPase (C5922, Sigma, USA) were thereafter immunodetected following cell permeabilization (20 min at room temperature, 150 ml PBS, 0.2% foetal calf serum, 0.5% saponin) and washed (1 ml cold PBS). Alternatively, incubation with mouse monoclonal anti-GFAP antibody (clone GA5, Sigma USA) (30 min at 4 C, 50 ml diluted antibody in PBS 0.05% saponin) was followed by incubation with anti-mouse IgG (30 min, 4 C, Alexa 660-GAM, Molecular Probes). Fluorescence was evaluated on the cytofluorimeter (FC500 MPL, Beckman Coulter). AQP4 and GLT1 expression following IgG treatment is presented in graph as decreased positive cell number compared to untreated cultures (in percent; Fig. 1A and B). 
Glutamine synthetase activity
Brain glutamine synthase enzymatic activity was routinely measured as previously described (Boksha et al., 2000) by the transferase reaction (ADP+L-Gln+NH2OH) and was determined by measuring -glutamyl hydroxamate formation. Cells were treated with cyclic adenosine monophosphate (Sigma Aldrich, 100 mM, 3 h) and subsequently with glutamate (Sigma Aldrich, 1 mM, 1 h). They were further dissociated using Polytron and homogenization buffer: phosphate buffer 0.1 M, glucose 70 mM, beta-mercaptoethanol 1.4 mM, bovine serum albumin 0.02% and glycerol vol/vol. The reaction mixture was as follows: imidazole-HCl, 50 mM, NH 2 OH, 50 mM, L-glutamine 100 mM, MnCl 2 0.5 mM, KH 2 AsO 4 25 mM and adenosine diphosphate 0.2 mM. After incubation at 37 C for 30 min, an equal volume of stop solution (0.37 M FeCl 3 , 0.3 M tricholoroacetic acid, 0.6 M HCl) was added.
The reaction was performed in a 96-well plate. Absorbance of the coloured complex formed by -glutamyl hydroxamate with iron was measured at 505 nm. Data are expressed in mole of -glutamyl hydroxamate per milligram protein per minute.
Glutamate quantification
Extracellular glutamate level was estimated using measure of amino acid content in glial cell medium, as reported (Touret et al., 2007) Fig. 2A ). We compared the effects of IgG NMO+ (n = 6), IgG NMOÀ (n = 2) and IgG Control (n = 2) on these glial cells. To mimic the prolonged contact of target tissue with NMO-IgG/AQP4 antibody that may occur in patients with Devic's neuromyelitis optica, glial cell cultures were treated for 24 h. Following IgG treatment, astrocyte and astrocyteoligodendrocyte cultures were examined for the expression of AQP4 and the glutamate transporter type1 (GLT1, analogous to excitatory aminoacid transporter 2 in human) and for the activity of glutamine synthetase (Fig. 1) . In untreated glial cells, AQP4 was detected by AQP4 and GFAP co-labelling (Fig. 1A) , and also at the surface of astrocytes by flow cytometry (Fig. 1A, top (Fig. 1A , bottom histogram and graph). The number of GFAP positive cells was not modified whatever the IgG origin (data not shown), indicating that the AQP4-positive cell decrease did not result from astrocytic death. The glutamate transporter GLT1 was detected in cultured glial cells by GLT1 and GFAP co-labelling, and again at the surface of astrocytes by flow cytometry (Fig. 1B, histogram) . In astrocytes treated with IgG NMO+ , flow cytometry showed a reduction of membrane GLT1 on GFAP positive astrocytes (Fig. 1B histogram  and 
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, respectively (P50.01) (Fig. 3A, graph (Parpura et al., 1994; Matute et al., 1997) . To answer this question, we analysed glutamate levels in the conditioned medium harvested from untreated and IgG NMO+ -treated glial cells (n = 2).
Extracellular glutamate was evaluated 2, 5 and 18 h posttreatment using capillary electrophoresis, as previously described (Touret et al., 2007) . Glutamate progressively accumulated in the (Fig. 4B) . We then analysed the co-expression of NMDA receptor (NR2B and NR1 subunits) and O4, an oligodendrocyte surface marker, in mixed glial culture. Co-labelling detected 86% NR2B positive and 37% NR1 positive among the O4 cell population (Fig. 4C, histograms) . Immunofluorescence confirmed NR2B and NR1 expression on cultured oligodendrocytes (Fig. 4C) . To validate our excitotoxic death hypothesis, we investigated whether IgG NMO+ -induced oligodendrocyte loss could be limited by blocking NMDA receptors. Astrocyteoligodendrocyte cultures were co-treated for 24 h with IgG (IgG NMO+ n = 5; IgG Control , n = 2) and D-AP5, a competitive antagonist of NMDA receptors. Treatment with D-AP5 partly protected oligodendrocytes from the IgG NMO+ -induced toxic effect (33 AE 4% decrease of CNPase positive cells with D-AP5 versus 45 AE 4% without D-AP5) (P = 0.08) (Fig. 4D) . The protective effect of D-AP5 on oligodendrocytes was also tested on optic Figure 4 A glutamate-mediated excitotoxicity induced by IgG NMO+ could be involved in the deleterious interaction between oligodendrocytes and astrocytes. (A) Glial cultures were treated with conditioned medium harvested from astrocyte and astrocyteoligodendrocyte cultures treated with IgG NMO+ (n = 5), IgG NMO-(n = 2) and IgG Control (n = 2). The effect of conditioned media on CNPase positive oligodendrocyte was evaluated using immunofluorescence (graph represents 24 cumulative data of two independent experiments, data expressed in per cent of decrease related to level in untreated cells). Conditioned medium from IgG NMO+ -treated astrocyte and astrocyte-oligodendrocyte cultures reduced the number of oligodendrocytes in a same extent (P = 0.1). In each experimental condition IgG NMO+ was more toxic than IgG NMOÀ (P50.01) and IgG Control (P50.0001). (B) Extracellular glutamate kinetic evaluation using capillary electrophoresis showed that glutamate progressively accumulated in the culture medium of cells exposed to IgG nerve treated with IgG NMO+ (n = 4) and IgG Control (n = 3). Again, the decrease in the number of oligodendrocytes following IgG NMO+ contact was partly reduced by D-AP5 treatment (not shown). Altogether, our results substantiate the hypothesis that, in our study models, IgG NMO+ -induced oligodendrocyte loss is associated with glutamate excitotoxicity.
In adult rat spinal cord and optic nerve, NMO-IgG bind astrocyte processes that closely wrap oligodendrocytes
Association of NMO-IgG-immunoreactive astrocyte processes and oligodendrocytes in tissues affected in Devic's neuromyelitis optica would support the view of a bystander affect of damaged astrocytes on oligodendrocytes. We investigated NMO-IgG immunoreactivity in rat optic nerve and spinal cord using NMO-IgG positive sera from patients with Devic's neuromyelitis optica (n = 6) and negative sera from patients with multiple sclerosis (n = 8) as a control. Our previous experiment showed that NMO-IgG immunoreactivity was predominantly present in the processes and soma of astrocytes on 4% paraformaldehyde fixed tissues (Supplementary Fig. 3 ). No staining was observed with control sera whereas all NMO-IgG positive sera from patients with Devic's neuromyelitis optica showed similar labelling. In rat spinal cord, NMO-IgG immunoreactivity displayed a mesh-like pattern organized in long fibre network throughout the white matter ( Fig. 5A; Supplementary Fig. 4 ) and concentrated in rim and rosette vasculocentric patterns within grey matter. Co-immunolabelling showed that reactivity for NMO-IgG, GFAP and AQP4 largely co-localized but not with neurofilament, a neuronal marker ( Supplementary Fig. 3A and B) . Similar distribution was observed in the optic nerve. NMO-IgG immunoreactivity organized along the astrocytic fibre network known to assemble along the nerve length (Butt and Kirvell, 1996) (Fig. 5A) . Again, NMO-IgG immunoreactivity co-localized with AQP4 and GFAP but not with Factor VIII, an endothelial cell marker (Supplementary Fig. 5A and B). As previously reported for AQP4 expression (Misu et al., 2007; Roemer et al., 2007) , NMO-IgG staining was prominent in the spinal cord and optic nerve in comparison to brain white matter (not shown). Supporting our hypothesis, dual labelling of NMO-IgG and CRMP5, a marker of oligodendrocyte, showed that NMO-IgG positive processes closely enfolded oligodendrocytes both in optic nerve and spinal cord (Fig. 5B) . Co-immunolabelling with MBP confirmed the close contact of NMO-IgG positive processes with myelin tracts. These observations suggest that a bystander effect of NMOIgG-damaged astrocytes on oligodendrocytes might occur in the nervous tissues affected by Devic's neuromyelitis optica.
Discussion
Our results confirm the pathogenic role of IgG isolated from neuromyelitis optica patients with NMO-IgG/AQP4 antibody (IgG
NMO+
). Using models based on IgG NMO+ -treated primary glial cultures and optic nerve, we showed that IgG NMO+ induced alteration and death of oligodendrocytes, possibly through an excitotoxic mechanism resulting from glutamate homeostasis disruption in astrocytes. The ability of NMO-IgG to bind AQP4 positive astrocytic processes in close contact with oligodendrocytes in the spinal cord and optic nerve suggests the possibility of disruption of glutamate homeostasis in Devic's neuromyelitis optica. There are increasing evidences for a direct role of NMO-IgG/ AQP4 antibody in the pathophysiology of Devic's neuromyelitis optica. Most of the studies have focused on NMO-IgG/AQP4 antibody-induced alteration of astrocytes, as AQP4, the target of NMO-IgG, is mainly expressed on astrocytes in the central nervous system (Hinson et al., 2007 (Hinson et al., , 2008 Vincent et al., 2008; Kinoshita et al., 2009; Sabater et al., 2009) . However, Devic's neuromyelitis optica lesions are also characterized by extensive demyelination and oligodendrocyte loss associated with axonal injury (Lucchinetti et al., 2002) and the link between astrocyte alterations and demyelination remains elusive. We hypothesized that lesion pathology of Devic's neuromyelitis optica could be driven by an altered cross-talk between damaged astrocytes and oligodendrocytes, as astrocytes are crucial for oligodendrocyte survival (Belin et al., 1997; Szymocha et al., 2000) . Using astrocyte-oligodendrocyte and astrocyte cultures, we showed the deleterious effect of IgG NMO+ on oligodendrocytes. These in vitro data were validated ex vivo on optic nerve, a typical white matter tract and an archetypal model tissue for studying glial cell physiology and interaction (Butt et al., 2004) . Prolonged application (24 h) of IgG NMO+ mimicked the suspected in situ effect of NMO-IgG/AQP4 antibody during Devic's neuromyelitis optica attacks. All experiments were performed with purified IgG isolated from sera of patients with Devic's neuromyelitis optica rather than total sera to avoid molecular signal other than autoantibody. It remains to be determined whether, in our study models, the NMO-IgG/AQP4 antibody itself or another autoantibody present in the purified IgG fraction are deleterious for glial cells. The minor effect of IgG NMOÀ and AQP4-absorbed IgG NMO+ towards oligodendrocytes, compared to the effect of IgG NMO+ , argues for the involvement of anti-AQP4 antibody in glial injury. However, it is likely that, as in other autoimmune diseases, there might be more than one target auto-antigen. A study using protein microarray has identified a possible autoantibody other than AQP4 in the serum of one patient with Devic's neuromyelitis optica (Lalive et al., 2006) . Eventually, testing cells and tissues from AQP4 knockout animals should define more precisely the role of AQP4 antibodies. Finally, purified IgG were used without complement in all experiments, as our objective was to analyse the effect of the autoantibody per se. The critical role of autoantibody associated with complement in Devic's neuromyelitis optica pathophysiology has already been well documented (Hinson et al., 2008 , Sabater et al., 2009 Saadoun et al., 2010) . However, autoantibody also acts as specific receptor agonist or antagonist, or alters antigen density in target cells (Diamond et al., 2009) . Recent data (Hinson et al., 2008) combines with ours to suggest that, besides complement activation, antibody-directed alteration of surface AQP4 could be involved in the pathophysiology of Devic's neuromyelitis optica. Moreover, this latter antibody function could accentuate the complement effect in Devic's neuromyelitis optica pathophysiology as oligodendrocytes are sensitized to complement attack following disruption of glutamate homeostasis (Alberdi et al., 2006) .
The loss of astrocyte driven by NMO-IgG/AQP4 antibody is most likely involved in Devic's neuromyelitis optica pathophysiology. Staining of GFAP is lost in recent Devic's neuromyelitis optica lesions also lacking AQP4 (Misu et al., 2007) . A marked increase of GFAP and S100b in the cerebrospinal fluid during acute Devic's neuromyelitis optica relapses has been associated with clinical severity and length of spinal lesions Petzold et al., 2010) . In vitro, NMO-IgG/AQP4 antibody can induce necrosis of astrocytes in a context of complement activation (Kinoshita et al., 2009; Sabater et al., 2009) . Our observations suggest that, in addition, a functional alteration of astrocytes might also be implicated. In our study models, long-time exposure of glial cells to IgG NMO+ , validated as containing AQP4 antibody, specifically led to a prolonged downexpression of both AQP4 and the glial glutamate transporter GLT1 at the astrocyte membrane. Such an effect has already been observed following short exposure of isolated astrocytes to NMO-IgG/AQP4 antibody (Hinson et al., 2008) . Given the prominent role of GLT1 in extracellular glutamate clearance (Danbolt et al., 1992) , downregulation at astrocyte membrane might be involved in the progressive increase of extracellular glutamate level detected in IgG NMO+ -treated glial cells. Extracellular glutamate elevation could also result from reduced glutamine synthetase activity as pharmacological inhibition of glutamine synthetase enhances exocytotic release of glutamate from astrocytes (Ni and Parpura, 2009 ). We show that glutamine synthetase activity was reduced in astrocytes following exposure to IgG NMO+ . The downregulation of AQP4 in response to IgG NMO+ could also participate in astrocyte homeostasis disruption. It is generally agreed that AQP4 plays a role in brain water control (Papadopoulos et al., 2004) ; however, recent works have indicated that functions of AQP4 in the central nervous system are broader than expected (Verkman, 2005) . In astrocytes, AQP4 has been functionally associated with the glutamate transporters GLAST and GLT1 and the inward rectifying K + channel Kir4.1. This macromolecular complex plays an important role in K + buffering, extracellular space expansion, neuronal transmission and excitability (Binder et al., 2004; Verkman, 2005; Zeng et al., 2007) , which could be impaired by NMO-IgG/AQP4 antibody. Overall, the NMO-IgG-mediated downregulation of glutamine synthetase activity, and of AQP4 and GLT1 on the astrocyte cell surface, suggests that alteration of glutamate homeostasis in astrocytes is a potential pathogenic mechanism in Devic's neuromyelitis optica. Our experiments demonstrate that astrocytes, when altered by IgG NMO+ , are toxic in vitro for oligodendrocytes and ex vivo for myelin through a bystander effect possibly involving glutamate. This led us to propose that the white matter injury observed in Devic's neuromyelitis optica lesions could be related to changes in astrocyte homeostasis and elevated extracellular glutamate level as a consequence. Several findings support this hypothesis. Astrocytes can release a variety of gliotransmitters, including glutamate (Parpura and Zorec, 2010) , and oligodendrocytes in the spinal cord and optic nerve are highly vulnerable to this main excitotoxic transmitter (Matute, 2006 ; Xu et al., 2008) . In optic nerve, blockade of the glutamate transporter GLT1, which is preferentially expressed on astrocyte processes close to oligodendrocytes, led to massive demyelination (Domercq et al., 2005; Arranz et al., 2008) . The role of glutamate NMDA receptors in such oligodendrocyte injury is likely. They are functionally expressed in the myelinating processes of oligodendrocytes and have higher glutamate affinity relative to -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (Karadottir et al., 2005) . Over-activation leads to disintegration of oligodendroglial processes in the optic nerve (Salter and Fern, 2005) and NMDA receptor blockade reduced damage to white matter in a model of demyelination (Wallstrom et al., 1996; Basso et al., 2008) . In our study model, NMDA receptor subunits were expressed on oligodendrocytes and treatment with the competitive NMDA receptor antagonist, D-AP5 partly reduced oligodendrocyte loss after IgG NMO+ exposure. Finally, a direct toxic effect of NMO-IgG/AQP4 antibody on oligodendrocytes, although not definitely excluded, remains highly hypothetical considering that AQP4 is not expressed by oligodendrocytes. Moreover we showed that IgG NMO+ had no direct effect on enriched oligodendrocyte primary cultures, neither on morphology nor survival. The involvement of AQP4 in the pathophysiology of Devic's neuromyelitis optica probably depends on its location within neural tissue as several pools of AQP4 have been described (Amiry-Moghaddam et al., 2004; Nagelhus et al., 2004) . AQP4 mainly accumulates in astrocyte end-feet membranes, at fluidparenchymal interfaces and the blood-brain barrier through -syntrophin anchorage. Independently of this anchorage, astrocyte also expresses AQP4 in non-end-feet membranes within parenchyma (Costa et al., 2007) . We showed here that NMO-IgG/ AQP4 antibody has the ability to bind both astrocyte end-feet around blood vessels and astrocytic processes that surround oligodendrocytes in the rat spinal cord and optic nerve. The close contact of NMO-IgG/AQP4 positive processes with oligodendrocytes and myelin tracts suggest that a bystander effect of NMOIgG-damaged astrocytes on oligodendrocytes might occur in the nervous tissues affected by Devic's neuromyelitis optica. NMO-IgG-induced dysfunction of perivascular astrocyte foot process could trigger an initial osmotic dysregulation as NMO-IgG positive sera significantly increased blood-brain barrier permeability in vitro (Vincent et al., 2008) . Then, NMO-IgG could easily cross the damaged blood-brain barrier and reach astrocytes in contact with oligodendrocyte, leading to astrocyte, oligodendrocyte and myelin dysfunction. To conclude, NMO-IgG/AQP4 antibody is toxic for cultured oligodendrocyte possibly through an excitotoxic mechanism following disruption of glutamate homeostasis in astrocytes. These experimental data suggest that neuromyelitis optica lesions, which are initiated by AQP4-antibody binding to AQP4 and activation of the classical complement pathway, could also result from downregulation of AQP4, GLT1 and glutamine synthetase with astrocyte dysfunction and oligodendrocyte damage.
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